Effects of chemokines on proliferation and apoptosis of human mesangial cells

BMC Nephrology

Bernhard Banas¹  Monika Merkle¹  Holger Schmid¹  Markus Wörnle¹ 

[1] Medical Policlinic, Ludwig-Maximilians-University, Munich, Germany

关键词: chemokine receptor;    chemokine;    apoptosis;    proliferation;    Mesangial cell;   

Others  :  1083439
DOI  :  10.1186/1471-2369-5-8

 received in 2004-01-11, accepted in 2004-07-20,  发布年份 2004

【 摘 要 】

Background

Proliferation and apoptosis of mesangial cells (MC) are important mechanisms during nephrogenesis, for the maintenance of glomerular homeostasis as well as in renal disease and glomerular regeneration. Expression of chemokines and chemokine receptors by intrinsic renal cells, e.g. SLC/CCL21 on podocytes and CCR7 on MC is suggested to play a pivotal role during these processes. Therefore the effect of selected chemokines on MC proliferation and apoptosis was studied.

Methods

Proliferation assays, cell death assays including cell cycle analysis, hoechst stain and measurement of caspase-3 activity were performed.

Results

A dose-dependent, mesangioproliferative effect of the chemokine SLC/CCL21, which is constitutively expressed on human podocytes was seen via activation of the chemokine receptor CCR7, which is constitutively expressed on MC. In addition, in cultured MC SLC/CCL21 had a protective effect on cell survival in Fas-mediated apoptosis. The CXCR3 ligands IP-10/CXCL10 and Mig/CXCL9 revealed a proproliferative effect but did not influence apoptosis of MC. Both the CCR1 ligand RANTES/CCL5 and the amino-terminally modified RANTES analogue Met-RANTES which blocks CCR1 signalling had no effect on proliferation and apoptosis.

Conclusions

The different effects of chemokines and their respective receptors on proliferation and apoptosis of MC suggest highly regulated, novel biological functions of chemokine/chemokine receptor pairs in processes involved in renal inflammation, regeneration and glomerular homeostasis.

【 授权许可】

   
2004 Wörnle et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Luster AD: Chemokines: Chemotactic cytokines that mediate inflammation. N Engl J Med 1998, 338:436-445.
• [2]Muller A, Homey B, Soto N, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A: Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
• [3]Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, Kitamura K, Matsushima N, Yoshida N, Nishikawa S, Kishimoto T, Nagasawa T: The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998, 393:591-594.
• [4]Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littmann DR: Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998, 393:595-599.
• [5]Mackay CR, Chemokines : What chemokine is that? Curr Biol 1997, 7:R384-386.
• [6]Rollins BJ: Chemokines. Blood 1997, 90:909-928.
• [7]Murphy PM, Baggiolini M, Charo IF, Herbert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, Power CA: International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000, 52:145-176.
• [8]Segerer S, Nelson PJ, Schlöndorff D: Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 2000, 11:152-176.
• [9]Banas B, Luckow B, Möller M, Klier C, Nelson PJ, Schadde E, Brigl M, Halevy D, Holthöfer H, Reinhart B, Schlöndorff D: Chemokine and chemokine receptor expression in a novel human mesangial cell line. J Am Soc Nephrol 1999, 10:2314-2322.
• [10]Gomez-Chiarri M, Hamilton TA, Egido J, Emancipator SN: Expression of IP-10, a lipopolysaccharide- and interferon-gamma-inducible protein, in murine mesangial cells in culture. Am J Pathol 1993, 142:433-439.
• [11]Romagnani P, Beltrame C, Annunziato F, Lasagni L, Luconi M, Galli G, Cosmi L, Maggi E, Salvadori M, Pupilli C, Serio M: Role for interactions between IP-10/Mig and CXCR3 in proliferative glomerulonephritis. J Am Soc Nephrol 1999, 10:2518-2526.
• [12]Banas B, Wörnle M, Berger T, Nelson PJ, Cohen CD, Kretzler M, Pfirstinger J, Mack M, Lipp M, Gröne HJ, Schlöndorff D: Roles of SLC/CCL21 and CCR7 in human kidney for mesangial proliferation, migration, apoptosis and tissue homeostasis. J Immunol 2002, 168:4301-4307.
• [13]Harrison DJ: Cell death in the diseased glomerulus. Histopathology 1988, 12:679-683.
• [14]Schlöndorff D, Nelson PJ, Luckow B, Banas B: Chemokines and renal disease. Kidney Int 1997, 51:610-621.
• [15]Heeg K, Reimann J, Kabelitz D, Hardt C, Wagner H: A rapid colorimetric assay for the determination of IL-2-producing helper T cell frequencies. J Immunol Methods 1985, 77:237-246.
• [16]Gonzales-Cuadrado S, Lopez-Armada MJ, Gomez-Guerrero C, Subira D, Garcia-Sahuquillo A, Ortiz-Gonzales A, Neilson EG, Egido J, Ortiz A: Anti-Fas antibodies induce cytolysis and apoptosis in cultured human mesangial cells. Kidney Int 1996, 49:1064-1070.
• [17]Berger T, Brigl M, Hermann JM, Vielhauer V, Luckow B, Schlöndorff D, Kretzler M: The apoptosis mediator mDAP-3 is a novel member of a conserved family of mitochondrial proteins. J Cell Sci 2000, 113:3603-3612.
• [18]Fernandes-Alnemri T, Litwack G, Alnemeri ES: CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem 1994, 269:30761-30764.
• [19]Roos A, Sato T, Maier H, van Kooten C, Daha MR: Induction of renal cell apoptosis by antibodies and complement. Exp Nephrol 2001, 9:65-70.
• [20]Krammer PH: CD95's deadly mission in the immune system. Nature 2000, 407:789-795.
• [21]Ortiz A, Lorz C, Egido J: New kids in the block: the role of FasL and Fas in kidney damage. J Nephrol 1999, 12:150-158.
• [22]Kerr JF, Wyllie AH, Currie AR: Apoptosis: a basic biological phenomen with wide-ranging implications in tissue kinetics. Br J Cancer 1972, 26:239-257.
• [23]Hale AJ, Smith CA, Sutherland LC, Stoneman VE, Longthorne VL, Culhane AC, Wiliams GT: Apoptosis: molecular regulation of cell death. Eur J Biochem 1996, 236:1-26.
• [24]Baker AJ, Mooney A, Hughes J, Lombardi D, Jonson RJ, Savill J: Mesangial cell apoptosis: The major mechanism for resolution of glomerular hypercellularity in experimental mesangial proliferative nephritis. J Clin Invest 1994, 94:2105-2116.
• [25]Shimizu A, Kitamura H, Masuda Y, Ishizaki M, Sugisaki Y, Yamanaka N: Apoptosis in the repair of experimental proliverative glomerulonephritis. Kidney Int 1995, 47:114-121.
• [26]Shimizu A, Masuda Y, Kitamura H, Ishizaki M, Sugisaki Y, Yamanaka N: Apoptosis in progressive crescent glomerulonephritis. Lab Invest 1996, 74:941-951.
• [27]Ortiz A, Lorz C, Justo P, Catalan MP, Egido J: Contribution of apoptotic cell death to renal injury. J Cell Mol Med 2001, 5:18-32.
• [28]Wang W, Tzanidis A, Divjak M, Thomson NM, Stein-Oakley AN: Altered signaling and regulatory mechanisms of apoptosis in focal and segmental glomerulosclerosis. J Am Soc Nephrol 2001, 12:1422-1433.
• [29]Kitching AR, Katerelos M, Mudge SJ, Tipping PG, Power DA, Holdsworth SR: Interleukin-10 inhibits experimental mesangial proliferative glomerulonephritis. Clin Exp Immunol 2002, 128:36-43.
• [30]Feld SM, Hirschberg R, Artishevsky A, Nast C, Adler SG: Insulin-like growth factor I induces mesangial proliferation and increases mRNA and secretion of collagen. Kidney Int 1995, 48:45-51.
• [31]Floege J, Eng E, Young BA, Alpers CE, Barrett TB, Bowen-Pope DF, Johnson RJ: Infusion of platelet-derived growth factor or basic fibroblast growth factor induces selective glomerular mesangial cell proliferation and matrix accumulation in rats. J Clin Invest 1993, 92:2952-2962.
• [32]Sano H, Ueda Y, Takakura N, Takemura G, Doi T, Kataoka H, Murayama T, Xu Y, Sudo T, Nishikawa S, Nishikawa S, Fujiwara H, Kita T, Yokode M: Blockade of platelet-derived growth factor receptor-beta pathway induces apoptosis of vascular endothelial cells and disrupts glomerular capillary formation in neonatal mice. Am J Pathol 2002, 161:135-143.
• [33]Campbell JJ, Bowman EP, Murphy K, Youngman KR, Siani MA, Thompson DA, Wu L, Zlotnik A, Butcher EC: 6-C-kine (SLC), a lymphocyte adhesion triggering chemokine expressed by high endothelium, is an agonist for the MIP-3β receptor CCR7. J Cell Biol 1998, 141:1053-1059.
• [34]Dieu MC, Vanbervliet B, Vicari A, Bridon JM, Oldham E, Ait-Yahia S, Briere F, Zlotnik A, Lebecque S, Caux C: Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998, 188:373-386.
• [35]Cyster JG: Leukocyte migration: scent of the T zone. Curr Biol 2000, 10:R30-33.
• [36]Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712.
• [37]Boehme SA, Lio FM, Maciejewski-Lenoir D, Bacon KB, Conlon PJ: The chemokine fractalkine inhibits Fas-mediated cell death of brain microglia. J Immunol 2000, 165:397-403.
• [38]Anders HJ, Vielhauer V, Kretzler M, Cohen CD, Segerer S, Luckow B, Weller L, Gröne HJ, Schlöndorff D: Chemokine and chemokine receptor expression during initiation and resolution of immune complex glomerulonephritis. J Am Soc Nephrol 2001, 12:919-931.
• [39]Topham PS, Csizmadia V, Soler D, Hines D, Gerard CJ, Salant DJ, Hancock WW: Lack of chemokine receptor CCR1 enhances Th1 responses and glomerular injury during nephrotoxic nephritis. J Clin Invest 1999, 104:1549-1557.
• [40]Anders HJ, Frink M, Linde Y, Banas B, Wörnle M, Cohen CD, Vielhauer V, Nelson PJ, Grone HJ, Schlöndorff D: CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration. J Immunol 2003, 170:5658-5666.